# Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
Canonical URL: https://biopharmsignal.com/news/IMVT/immunovant-to-report-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2026-and-provide-business-update-on-wednesday-may-20-2026
Ticker: IMVT
Company: Immunovant
Source: Immunovant
Published: 2026-05-11 20:05 EST
Original Source URL: https://www.immunovant.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-05-20 11:00 EST — [Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026](https://biopharmsignal.com/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2026) — Source: Immunovant
- 2026-05-11 20:05 EST — [Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026](https://biopharmsignal.com/news/IMVT/immunovant-to-report-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2026-and-provide-business-update-on-wednesday-may-20-2026) — Source: Immunovant
- 2026-04-02 09:00 EST — [Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)](https://biopharmsignal.com/news/IMVT/immunovant-announces-phase-3-study-results-for-batoclimab-in-thyroid-eye-disease-ted) — Source: Immunovant
- 2026-02-06 12:00 EST — [Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025](https://biopharmsignal.com/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-third-quarter-ended-december-31-2025) — Source: Immunovant
- 2026-01-23 22:25 EST — [Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026](https://biopharmsignal.com/news/IMVT/immunovant-to-report-financial-results-for-the-third-quarter-ended-december-31-2025-and-provide-business-update-on-friday-february-6-2026) — Source: Immunovant
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)